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Transforming growth factor b (TGF-b) signals
through two transmembrane serine/threonine kinases,
known as TbR-I and TbR-II. Several lines of evidence
suggest that TbR-II acts as a primary receptor, binding
TGF-b and phosphorylating TbR-I whose kinase activity
then propagates the signal to unknown substrates. We
report an interaction between TbR-I and the farnesyl-
protein transferase-a subunit (FT-a) both in a yeast two-
hybrid system and in mammalian cells. These findings
raise the possibility that TGF-b might regulate cellular
functions by altering the ability of FT-a to catalyze iso-
prenylation of targets such as G proteins, lamins, or
cytoskeletal components. However, we provide evidence
that TGF-b action does not alter the overall protein iso-
prenyl transferase activity in Mv1Lu mink lung epithe-
lial cells. In fact, the b subunits of farnesyl transferase
and geranylgeranyl transferase, which are necessary for
the activity of FT-a, prevent the association of FT-a with
TbR-I. Furthermore, farnesyl transferase activity is
shown to be dispensable for TGF-b signaling of growth
inhibitory and transcriptional responses in these cells.
These results suggest that the interaction between
TbR-I and FT-a does not affect the known functions of
these two proteins.
TGF-b1 is a multifunctional cytokine that controls prolifer-
ation, differentiation, and many other functions in the cell
(1–4). The anti-mitogenic effects of TGF-b in particular have
attracted much attention. By inhibiting cyclin-dependent ki-
nases, TGF-b can override the action of mitogens without di-
rectly blocking their signal transduction pathways (5–8).
TGF-b initiates signaling at the membrane by contacting two
types of transmembrane serine/threonine kinase receptors, the
type I and II receptors (TbR-I and TbR-II) (9–12). These recep-
tors belong to a family that also includes receptors for other
TGF-b-related factors such as activins and bone morphogenic
proteins (BMPs) (4). Type II receptors bind ligand present in
the medium, and this complex associates with and phosphoryl-
ates type I receptors (12). Phosphorylation is at serine and
threonine residues clustered in the GS domain, a region just
upstream of the kinase domain and conserved in all type I
receptors, and mutation of these sites blocks TGF-b signaling
(13). Certain mutations in the GS domain generate a constitu-
tively active TbR-I that does not require the presence of ligand
or TbR-II for signaling (14). These observations suggest that
TbR-I, acting downstream of TbR-II, is directly involved in
transducing TGF-b signals to downstream substrates.
In order to search for proteins that interact with the cyto-
plasmic domain of TbR-I, we used protein interaction cDNA
cloning in yeast. This led to the identification of farnesyl trans-
ferase-a (FT-a) as a TbR-I interacting protein. FT-a is a shared
subunit of heteromeric transferases that attach farnesyl or
geranylgeranyl moieties to a variety of proteins that play key
roles in signal transduction, protein secretion, and cytoskeleton
assembly (15, 16). We provide evidence that the interaction
between TbR-I and FT-a can also take place in mammalian
cells. Similar observations were reported by two other groups
(17, 18) while this paper was in preparation. Additionally, we
have analyzed the physiological relevance of this interaction.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Screening and Interaction Assay—A HeLa cDNA
library was screened by the two-hybrid system essentially as described
(19, 20) using as bait the wild type cytoplasmic domain of TbR-I (amino
acids 148–503) (10) or this domain containing the T204D mutation (14).
For interaction assays, the cytoplasmic domains of TbR-II (190–576)
(9), TSR-I (amino acids 144–503) (11), ActR-I (amino acids 147–509)
(11), ActR-IB (amino acids 150–505) (22), TbR-I wild type or mutated
versions were fused in frame to the LexA DNA binding domain in the
vector pEG202 (19). Yeast transformation and b-galactosidase assays
were done as described (20, 21).
Mammalian Expression Vectors and Transfections—The human
FT-a cDNA (15) was modified by polymerase chain reaction to encode
this protein with the Flag epitope sequence at the C terminus and
subcloned into the mammalian expression vector pCMV5. Human FT-b
and GGT-b cDNAs in the pcDNA3 vector were generous gifts of Drs.
Joseph Goldstein and Michael Brown. The generation of mutant as well
as chimeric receptors and reporter constructs had been previously de-
scribed (14, 22). The cell lines COS-1, Mv1Lu, and R-1B/L-17 were
cultured and transiently transfected with the indicated vectors (11, 22).
Immunoprecipitation and Western Blotting—Precipitation with anti-
Flag antibodies (IBI-Kodak) or Ni21-NTA-agarose (Qiagen) was done as
described (20). Western immunoblotting with anti-Flag or anti-TbR-I
antibodies was done using a 1:2000 dilution of these antibodies, a
1:5000 dilution of secondary antibodies, and the ECL detection system
(Amersham Corp.). Monoclonal antibodies against TbR-I were raised
using a juxtamembrane peptide sequence as described previously (10).
Metabolic Labeling—Cell labeling with [3H]mevalonolactone (23)
and with [35S]methionine or [32P]phosphate (13, 24) was done as
described.
In Vitro Ras Farnesylation Assay—Mv1Lu cells were incubated for
1 h with the indicated concentrations of TGF-b and subsequently lysed
in 20 mM Tris, 10 mM MgCl2, 5 mM ZnCl2, and 5 mM dithiothreitol, pH
7.4. After a brief sonication, 1 mM [3H]farnesyl pyrophosphate (DuPont
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NEN) and 100 mM bacterially expressed human Ha-ras was added to
cell lysates and incubated for 40 min at 30 °C. Samples were analyzed
by SDS-PAGE and autoradiography or by precipitation with trichloro-
acetic acid and counted. The farnesyl transferase inhibitor L-744-832
was a generous gift of Neal Rosen, MSKCC, and Allan Oliff, Merck (25).
RESULTS
We generated bait constructs for a yeast two-hybrid system
(19) using cDNAs encoding the human TbR-I cytoplasmic do-
main, either wild type or containing the T204D mutation (Fig.
1A). This mutation elevates the kinase activity of TbR-I in vitro
and endows this receptor with the ability to signal in the
absence of TGF-b or TbR-II (14). Screening of a HeLa cell
cDNA library with either bait yielded three major classes of
cDNAs. Two of these encoded, respectively, the FK506/rapamy-
cin binding protein FKBP12 and the BMP type II receptor
BMPR-II, both of which have been previously described as
TbR-I interacting proteins in the yeast two-hybrid system (20,
26, 27). The third class of cDNAs isolated in these screenings
encodes FT-a. This class accounted for 25% of all clones iso-
lated with TbR-I as bait, and 40% of those isolated with TbR-
I(T204D) as bait (of over 100 clones analyzed in each case). The
isolated FT-a clones encoded the full-length protein or lacked
no more than 79 amino acids at the N terminus, suggesting
that the interaction with TbR-I requires most of the FT-a
protein.
FT-a interacted weakly or not at all with the cytoplasmic
domains of TbR-II (9), the activin type I receptor ActR-I (11),
the mixed specificity type I receptor TSR-I (11), or with empty
vector (Fig. 1B). However, FT-a interacted strongly with the
cytoplasmic domain of the activin type I receptor ActR-IB (Fig.
1B), which has high sequence similarity (90% identity) to that
of TbR-I (22). To analyze the structural requirements of TbR-I
for its interaction with FT-a, we used baits containing muta-
tions that are known to alter the kinase activity of TbR-I and
its signaling ability in mammalian cells. The (K232R) bait,
which contains a mutation that eliminates kinase activity in
TbR-I (13), interacted very weakly with FT-a, whereas the
(T204D) bait interacted with FT-a more strongly than the wild
type bait (Fig. 1B). Curiously, mutations that eliminate TbR-II
phosphorylation sites in the TbR-I GS domain and prevent
signaling in mammalian cells (13, 14) increased the interaction
of the TbR-I bait with FT-a (Fig. 1B). A similar result was
obtained with a bait containing a full replacement of the GS
domain with an unrelated juxtamembrane sequence of TbR-II
(construct TbR-I (IIGS)) (Fig. 1B), indicating that the GS do-
main is not directly involved in the interaction.
In order to investigate these interactions in mammalian
cells, FT-a was tagged with the Flag epitope sequence at its N
terminus and transfected into COS-1 cells alone or in combi-
nation with full-length TbR-I constructs. The latter were
tagged at the C terminus with a hexahistidine sequence that
binds to Ni21-NTA-agarose. An interaction between the trans-
fected TbR-I and FT-a was demonstrated by incubating the cell
lysates with Ni21-NTA-agarose beads followed by immunoblot-
ting of the bound material using Flag antibody (Fig. 2A). In
contrast to the results in yeast, the interaction with FT-a was
not detectably affected by the mutations K232R or T204D in
TbR-I. Cotransfection of TbR-II and addition of TGF-b were
also without effect on the association between TbR-I and FT-a,
as judged from the amount of coprecipitated FT-a (Fig. 2A).
Metabolic labeling of these transfectants with [35S]methionine
and [32P]phosphate followed by precipitation of total FT-a with
anti-Flag antibody indicated that FT-a is a phosphoprotein in
the absence of TGF-b or cotransfected receptors (Fig. 2B). No
change in the ratio of 32P/35S labeling of FT-a was observed in
cells cotransfected with the wild type, kinase-defective, or con-
stitutively active TbR-I constructs or with both TbR-I and
TbR-II in the presence of TGF-b (Fig. 2B). Similar experiments
using an untagged FT-a construct and precipitation with a
FT-a monoclonal antibody (28) also yielded no evidence of TGF-
b-induced FT-a phosphorylation (data not shown).
The question was raised as to whether TbR-I recognized
FT-a as part of a holoenzyme with FT-b or GGT-b. In experi-
ments designed to test this possibility, we observed that co-
transfection of the b subunits inhibited the interaction of FT-a
with TbR-I (Fig. 3). Transfection of FT-b or GGT-b generated
holoenzyme complexes with cotransfected FT-a while it inhib-
ited the association of FT-a with TbR-I. Controls showed that
this effect was not due to a decreased expression of FT-a or
TbR-I (Fig. 3), suggesting that TbR-I does not recognize the
isoprenyl transferase holoenzymes.
In order to determine the functional consequence of the in-
FIG. 1. Analysis of the interaction between FT-a and various
baits in yeast. A, schematic representation of TbR-I with the extra-
cellular and transmembrane domains (dashed box) and the cytoplasmic
region (solid box). The position of the GS domain (black box), the kinase
domain, and various mutations used in this study are indicated. B,
Saccharomyces cerevisiae EGY48 was transformed with the lacZ re-
porter gene pSH18–34 bearing eight LexA binding sites, a vector en-
coding the indicated receptor cytoplasmic domains as LexA fusion pro-
teins, and a full-length FT-a vector. b-Galactosidase activity was
determined from four colonies of each strain. Values were normalized
relative to the activity of cells transformed with empty vector. The
experiment was repeated twice with the same results.
FIG. 2. FT-a interaction with TbR-I and phosphorylation in
mammalian cells. COS-1 cells were transfected with FT-a tagged with
the Flag epitope and different TbR-I constructs tagged with a hexahis-
tidine sequence. Assays were done 2 days after transfections. A, histi-
dine-tagged TbR-I receptors were isolated from cell lysates using Ni21-
NTA-agarose, separated by SDS-PAGE, and then immunoblotted with
anti-Flag antibody to detect FT-a (upper panel) or anti-TbR-I as a
control (lower panel). B, cells transfected with the indicated constructs
were metabolically labeled with [35S]methionine (lower panel) or
[32P]phosphate (upper panel). FT-a was immunoprecipitated with anti-
Flag antibody and resolved on SDS-PAGE.
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teraction between FT-a and TbR-I, we tested the effect of
TGF-b on protein isoprenylation. Mv1Lu epithelial cells were
used since they are highly responsive to TGF-b. Cells were
metabolically labeled with [3H]mevalonolactone, a biosynthetic
precursor of both farnesyl and geranylgeranyl pyrophosphate.
Incubation for 8 h with physiological concentrations of TGF-b
did not modify the level of 3H incorporation into Triton-soluble
proteins detectable under these conditions (Fig. 3A). A labeled
protein of 20 kDa (presumably a small G protein; Ref. 23)
migrated slightly faster after cell treatment with TGF-b (Fig.
4A). TbR-I has no consensus isoprenylation motif and did not
become labeled in [3H]mevalonolactone-labeled cells (data not
shown). Farnesyl transferase activity assayed in cell lysates
with recombinant Ha-ras as a substrate was similar in control
and TGF-b-treated cells (Fig. 4B). Therefore, TGF-b action
does not significantly alter the overall protein isoprenyl trans-
ferase activity in the cell.
Finally, we determined the effect of farnesyl transferase
inhibitor L-744-832 (25) on TGF-b responsiveness in Mv1Lu
cells. This agent blocks farnesyl transferase activity at 20 mM or
lower concentrations in diverse cell types (25) including Mv1Lu
cells.2 Mv1Lu cell proliferation was inhibited half-maximally
by ;20 mM L-744-832 and maximally by 40 mM L-744-832 (Fig.
5A). Mv1Lu cells respond to TGF-b with increased transcrip-
tion of plasminogen activator inhibitor-1 (22). Using a lucifer-
ase reporter construct (p3TP-lux) that contains the TGF-b re-
sponse region of the plasminogen activator inhibitor-1
promoter (22), the luciferase response to TGF-b was not af-
fected by addition of 20 mM L-744-832 and was decreased by 40
mM L-744-832 but only at the lower (,10 pM) TGF-b concentra-
tion range (Fig. 5B). In experiments designed to determine the
effect of L-744-832 on the growth inhibitory response to TGF-b,
a partial inhibition of 125I-deoxyuridine incorporation into
DNA observed with 20 mM L-744-832 was simply additive to the
inhibitory effect of TGF-b (Fig. 5C). These results suggest that
farnesyl transferase activity is not essential for TGF-b signal-
ing in Mv1Lu cells and has little or no participation in the two
TGF-b responses analyzed here.
DISCUSSION
We have used a yeast two-hybrid cloning system to search for
proteins that interact with the cytoplasmic domain of TbR-I
since this is a downstream component of the TGF-b receptor
system. Separate screenings of a HeLa cell cDNA library with
either the wild type TbR-I cytoplasmic domain or a constitu-
tively active mutant version yielded multiple isolates of three
different classes of clones. One class corresponds to the BMP
type II receptor BMPR-II previously shown to interact with
TbR-I in yeast (20, 27). Another class corresponds to the
FK506- and rapamycin-binding protein FKBP-12 whose inter-
action with TbR-I has also been previously documented and
remains of unknown significance (26). The third class, as re-
ported here, are clones encoding FT-a. While this report was in
preparation, both Kawabata et al. (17) and Wang et al. (18)
using the same approach reported an interaction of TbR-I with
FT-a and proposed that this interaction might regulate the
activity of the enzyme and explain the antiproliferative effects
of TGF-b. Here we provide evidence for this interaction in
mammalian cells and address the question of its physiological
significance.
TbR-I has no consensus isoprenylation motif and was not
isoprenylated in our assays. Therefore, it is unlikely that TbR-I
is a substrate of FT-a. On the other hand, the kinase activity of
certain TbR-I constructs correlates with their ability to interact
with FT-a in yeast, and similar findings have been made by
Kawabata et al. (17). Recombinant TbR-I kinase is able to
phosphorylate FT-a in vitro (17).3 However, some of our evi-
dence challenges the notion that TbR-I association with FT-a
simply reflects a kinase-substrate recognition event. Mutations
that eliminate ligand-dependent phosphorylation sites in the
GS domain actually increase the interaction of TbR-I with FT-a
in yeast even though they decrease the kinase activity of TbR-I
and block TbR-I signaling activity (14). Furthermore, in con-
trast to their effect on the receptor-FTa interaction in yeast,
2 L. Sepp-Lorenzini and N. Rosen, personal communication. 3 M. Kretzschmar and J. Massagué, unpublished work.
FIG. 3. Effect of expression of isoprenyl transferase b subunits
on the receptor-FT-a interaction. COS-1 cells were transfected with
0.5 mg of plasmids encoding Flag-tagged FT-a and hexahistidine-tagged
TbR-I, respectively, and increasing amounts (0.025, 0.15, and 1 mg) of
plasmids encoding FT-b or GGT-b or empty vector. After 2 days, cells
were metabolically labeled with [35S]methionine for 2 h. FT-a was
precipitated with anti-Flag antibody and subjected to SDS-PAGE and
autoradiography (upper panel). TbR-I was retrieved with Ni21-NTA-
agarose, separated by SDS-PAGE, and immunoblotted either with anti-
Flag antibody to detect FT-a (middle panel) or TbR-I antibody (bottom
panel).
FIG. 4. TGF-b effects on protein isoprenylation activity. A,
Mv1Lu cells were metabolically labeled with [3H]mevalonolactone and
treated with different TGF-b concentrations for 8 h. Triton-soluble
proteins were resolved by SDS-PAGE and visualized by autoradiogra-
phy. B, extracts of cells treated with increasing TGF-b concentrations
were assayed for farnesyl transferase activity using H-ras and [3H]far-
nesyl pyrophosphate as substrates. Labeled Ha-ras was visualized by
SDS-PAGE and autoradiography.
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the K232R and T204D mutations had no detectable effect on
this interaction in COS-1 cells. We observed no change in the
phosphorylation level of FT-a by cotransfection of receptors
and TGF-b addition to the cells, although this result stands in
contrast to those of Wang et al. (18) who reported ligand-
induced phosphorylation of FT-a. Further investigation is re-
quired to determine the reason for this discrepancy and the
basis for the interaction between TbR-I and FT-a.
The overall level of protein isoprenylation in intact cells or
the Ras farnesylation activity in cell extracts is not affected by
TGF-b addition to Mv1Lu cells, a cell line that is strongly
growth-inhibited by this factor. TGF-b could have altered iso-
prenyl transferase activity in a transient manner that escaped
detection in our experiments. However, this seems unlikely
since protein isoprenylation has a relatively long half-life in the
cell and is not known to undergo a highly dynamic regulation
(16). We also considered the possibility that farnesyl transfer-
ase activity might be required for TGF-b signaling. This ques-
tion was investigated with the use of the farnesyl transferase
inhibitor L-744-832. This agent inhibits cell proliferation by
inhibiting protein farnesylation (25). Yet, at a concentration
that blocks cell proliferation, L-744-832 has little effect on the
basal or TGF-b-activated expression of a reported gene in these
cells. On the other hand, the growth inhibitory effects of L-744-
832 and TGF-b in Mv1Lu cells are additive with no evidence of
synergy. These results suggest that farnesyl transferase activ-
ity does not participate in these TGF-b responses.
Significantly, in addition to forming complexes with FT-a,
the cotransfected FT-b or GGT-b subunits inhibit the interac-
tion of FT-a with TbR-I. Thus, the receptor can recognize
isolated FT-a but not the holoenzymes and, therefore, may not
be associated with isoprenyl transferase activity. It is possible
that the receptor acts as a negative regulator of isoprenyl
transferases by sequestering FT-a. However, overexpression of
TbR-I alone does not cause the alterations in proliferation and
other cellular functions that might be expected from an effi-
cient sequestration of endogenous FT-a. Alternatively, FT-a
might have a high tendency to associate with b subunits and, in
their absence, with other proteins that for unknown reasons
include TbR-I. In any case, we find no evidence that TbR-I or
FT-a affects the known functions of each other. The hypothesis
that Ras activity and cell proliferation are regulated through a
direct interaction of the TGF-b receptor with farnesyl transfer-
ase is not supported by the evidence to date.
Acknowledgments—We are indebted to N. Rosen, L. Sepp-Lorenzino,
and A. Oliff for help with enzyme and cell proliferation assays and their
gift of farnesyl transferase inhibitor and to J. Goldstein, M. Brown, and
G. James for helpful discussions and their gift of FT-a monoclonal
antibody and b subunit vectors. We thank R. Brent for plasmids and the
HeLa cDNA library.
REFERENCES
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